Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BETS NEWS OUT!!!!
SeanieMac Confirms 2Q On Track to Double Revenue of First Quarter
New Platform Projected Launch Date Less Than 60 Days
HUNTINGTON, NY -- (Marketwired) -- 06/17/16 -- SeanieMac International Ltd. (OTC PINK: BETS) announced today that its second quarter revenue is on track to double the revenue achieved during the first quarter of 2016. First quarter revenues (turnover) were US$2.82 million. Currently, second quarter revenues are $4.5 million with 2 weeks left in the quarter. Two million in revenue was booked during the last two weeks.
The Company also announced that it has revised the projected launch date for its new platform from September to mid-August. Development and coding of the platform has been active for weeks and training on the new platform is scheduled to begin late June. The Company believes there will be a sharp increase in revenues immediately following the launch.
About SeanieMac
SeanieMac Limited is a UK gaming company. It owns and operates "www.apollobet.com", an online sports and casino wagering web-based platform serving gamblers directly under the brand name SeanieMac.com.
The Company's mission is to provide a market-leading, user-friendly website for online gambling, including sports betting and casino gaming (traditional casino, live casino, poker, bingo and interactive skilled games). The Company does not market to U.S. residents and, hereby, specifically discourages them from attempting to access its wagering services.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of SeanieMac International, Ltd. and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements regarding our expectations regarding amounts staked and gross profits and our marketing initiatives. Such risks and uncertainties include, among other things, the uncertainty regarding consumer preferences, a decline in the popularity of our website and competition in the online gambling industry. SeanieMac assumes no obligation and does not intend to update these forward-looking statements.
A further description of risks and uncertainties can be found in SeanieMac International, Ltd.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in its reports on Form 10-Q and Form 8-K.
SeanieMac International Ltd.
Shane O'Driscoll
investorrealtions@seaniemacinternational.com
Source: SeanieMac International, Ltd.
$ARCS MULTI BAGGER COMETH
http://www.otcmarkets.com/stock/ARCS/quote …
DIGX up 50%. Super thin L2. great news few days ago and still under the radar. Something is coming.
Here's news from few days ago....AS reduction, no toxic debt.
$EXAD GREEEEN... $MYLI LOADING... $SPOM BUYIN DIP.
DIGX news.....AS,OS reduction, no toxic debt
DIGX Company Reduces Shares Authorized, Shares Outstanding, and Debt
Dig-it Underground, Inc. Provides Details Regarding Improved Balance Sheet
Company Reduces Shares Authorized, Shares Outstanding, and Debt
DALLAS, TX -- (Marketwired) -- 05/31/16 -- Dig-it Underground Inc. (OTC PINK: DIGX) today announced that the Board of Directors has approved a reduction of its authorized common shares by 100,000,000. Also, the Company accepted for cancellation and return to the treasury 90,000,000 shares of common stock that were held by a former officer, reducing the number of issued and outstanding shares to 1,785,612,000. The Company will file an amendment to its Articles of Incorporation with the Nevada Secretary of State for the reduction of authorized shares within the next 30 days.
Additionally, the Company has significantly reduced its short-term revolving loan balance by $100,000, with the remaining long-term liabilities consisting of two separate installment loans. One loan is a traditional commercial real estate loan and the other is a medical equipment bank loan that has four years remaining.
"We have worked long and hard to make these improvements to our balance sheet, and are proud to be able to provide our shareholders with a breakdown of how we were able to make these reductions," said Leonid Chernyakhovsky, President of Dig-it Underground, Inc. "Neither our short-term nor long-term liabilities are secured nor collateralized by securities, which allows us to continue building our brand through strategic growth without any toxic financing to hold us back."
Forward-Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Dig-it Underground, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Dig-it Underground, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
THANKZ 4 DA CHART YO... HOOK ME UP WIT A $MYLI CHART ALSO...
$MYLI & $EXAD CHART PLEAZ... LOW FLOATERZ.
$MYLI QB STOCK 250MIL A/S O.G....52WK LOW. $EXAD 52WK LOW.. BAGAINZ.
$MYLI 250MIL A/S QB STOCK...52WK LOW YO... EXAD 200MIL A/S 52WK LOW YO...
$MYLI 250MIL A/S QB STOCK...52WK LOW YO... EXAD 200MIL A/S 52WK LOW YO...
$MYLI JUST LIKE APYP WAZ...QB STOCK 300MILLY A/S .002s.
$MYLI JUST LIKE APYP WAZ...QB STOCK 300MILLY A/S .002s.
$SPOM LUKIN 2 BREAKOUT FROM CURRENT CHANNEL... 300MIL A/S.....0014. REMINDZ ME OF MY GEQU WHEN IT WAZ IN TEENZ. GOING LONG ON $SPOM.
$EXAD D-BOY ALERT...200MIL A/S.. .0015 52WK LOW... NOW BRAINER PEPZ.. LOAD UP AND GET $$$$
BOUT TO CRANK THIZ CHIT BAK UP.... D-BOY ALERT $MYLI .002 250MIL A/S QB STOCK...52WK LOW...SILVER PLAY... LOAD UP!!
Get some news going for $ECOS. Sooo thin right now!
http://www.ecolocap.com/
FROT looks ready to go!
FROT NO MORE RS! BOOM
~ APYP = .0050 Test Coming!!
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
~MLCG~ LOOKING LIKE BIG TIME PLAYERS STARTING TO SEE THE HUGE POTENTIAL! GET YOUR CHEAPIES WHILE YOU STILL CAN!
14 mill float $GVSI nvsos updated name change to Long beard breweries inc!!
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=DEUhE5iwuIfrZskPprSojg%253d%253d
$PMCB Cardica News and Response Bodes Well for Pharmacyte Biotech
Cardica, Inc. (NASDAQ:CRDC) has given the market a not-so-gentle reminder that biotechnology and medical devices aren't under the same fire as biopharmaceuticals. Time to put Pharmacyte Biotech Inc. (OTCMKTS:PMCB) back on the radar, for the same reason.
After more than a year's worth of miserable performance from the stock, Cardica, Inc. (NASDAQ:CRDC) shares are soaring, up 36% today on the heels of news that its surgical stapling device has been cleared by the FDA for far more uses than had been previously permitted. The news doesn't come as a complete shock to CRDC owners, though that's certainty didn't start to materialize until after January 7th when the company announced a new partnership agreement with Intuitive Surgical that vaguely suggested good news was on the way. And, even the inkling of good news didn't do as much for Cardica shares as the confirmed news did this morning.
In a bigger sense, while pharmaceuticals and specialty drugs were under fire during the latter half of 2015, that weakness also unfairly pressured makers of biotech devices lower. The rebound from CRDC helps to imply the group is in rebound mode now, so for investors looking to pick up other compelling but speculative biotech device ideas may want to add Pharmacyte Biotech Inc. (OTCMKTS:PMCB) if not their portfolio.
Pharmacyte Biotech is the developer of a biotechnology called Cell-In-a-Box, which is making the healthcare industry rethink what's possible in terms of drug delivery.
Pharmacyte Biotech has, in simplest terms, perfected the elusive art of live cell encapsulation. In other words, PMCB is successfully doing what most researchers and biotech companies have struggled to do well (and been unable to do for the long haul) by encapsulating live cells in a package that (1) is small enough to be implanted into a human body, (2) durable enough to resist a body's immune response, and (3) porous enough to allow the healthy cells living inside the encapsulation to operate normally when that patient's own cells aren't doing their job. Cell-in-a-Box is that biotechnology.
It's as much of a process as it is a molecular structure. The first step in their creation is a mix of live cells (that ultimately spur or even become the therapy) and a proprietary polymer that is then dropped into another proprietary polymer. The two polymers react to form a solid object about the size of the head of the pin, with the still-living cells beneath the shell of the tiny sphere. Though only a few millimeters across, the number of living cells inside the tiny bead-sized capsule can be in the thousands.
While it's not a new idea, Pharmacyte has upped the ante, so to speak, on encapsulation. These capsules allow the cells inside to receive nutrients from a body as well as emit certain chemicals, yet they don't let antibodies in and potentially kill the outside, unrecognized cells the way an immune system normally would. And, unlike most other encapsulation efforts, the capsule itself isn't known to degrade.
The implications for such a technology are almost limitless, although Pharmacyte is first focusing on two arenas... pancreatic cancer, and type 1 diabetes.
On the diabetes front, the cells "in the box" would be insulin-producing engineered Magellan cells inside the pinhead-sized beads, which are then surgically deposited in the leg, near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
As for pancreatic cancer, Cell-in-a-Box is a means of placing thousands of live cells that produce a P450 enzyme inside the capsule, which can activate an otherwise inactive form of cancer drug ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
It blurs the line between biotechnology device and biopharmaceuticals... as most next-generation treatments should.
Though there's still more work to be done, as most veteran traders can attest, the market rewards biotech companies reaching milestones by pushing the stock upward. The PMCB premise alone already has plenty of people interested, and with 2016 being a year with lots of catalysts in the queue, now's the time to start taking a closer look.
With that in mind, just this morning the company updated its explanation of its biotechnology and added some new information about Cell-In-a-Box. Newcomers as well as those familiar with Pharmacyte Biotech will want to take a look right here.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/6150096.htm
$ISBG Watch “ISBG” on @Vimeo https://vimeo.com/139474480
$SFOR: ONE OF THOSE RARE MOMENTS, SEE WHY:
SFOR DD:
http://www.strikeforcecpg.com/
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121228935
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
NGEY news....
THERMAL, Calif., March 10, 2016 /PRNewswire/ -- New Global Energy, Inc. (OTCQB: NGEY) ("the Company"), a public company focused on Aqua-Farming, Agriculture, and Health & Wellness, announced today that its tilapia season is in full swing and on schedule to produce record breaking revenue.
http://photos.prnewswire.com/prnvar/20160310/342886
At Aqua Farming Tech, NGE's wholly owned subsidiary, there are two spawning seasons in the Spring and Fall that produce one million tilapia each that we expect to be a total of two million annually. This month, the Fall season's tilapia are coming to full maturity at approximately one pound each and are preparing to go to market at $3.60 per pound (delivered) or $3.00 per pound (picked up at the farm) with price increases expected.
"We are very pleased that our tilapia farm operation in the Coachella Valley is more profitable and sustainable than ever before," said Chief Executive Officer Perry D. West. "As soon as our tilapia reach full market size we are ready to ramp up sales in order to meet increased consumer demand for quality seafood. 2016 will be a record year for our farms."
New Global Energy's farms are uniquely suited to grow tilapia, which is a tropical fish, because of the area's warm climate and the availability of warm fresh water from geo-thermally heated wells. The company's proprietary fish feeding methodology saves up to 70% on overall feed costs. The fish are fed nutrient rich algae and other aquatic plants for their first four months in grow-out ponds that represent a natural environment.
About New Global Energy, Inc.
New Global Energy, Inc. (www.newglobalenergy.net) is a public company focused on acquiring high-growth firms, assets and properties in the Aqua-Farming, Agriculture, and Health & Wellness industries. The trading symbol is NGEY traded on the OTCQB. New Global Energy seeks to create sustainable projects and protect the environment.
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
For more information please contact:
Charlotte Luer, Director of Investor Relations
cluer@newglobalenergy.net
+1-239-404-6785
Photo - http://photos.prnewswire.com/prnh/20160310/342886
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tilapia-production-fully-underway-at-new-global-energy-inc-300234170.html
SOURCE New Global Energy, Inc.
TGLO CRAZY RUN
$PMCB Cardica News and Response Bodes Well for Pharmacyte Biotech
Cardica, Inc. (NASDAQ:CRDC) has given the market a not-so-gentle reminder that biotechnology and medical devices aren't under the same fire as biopharmaceuticals. Time to put Pharmacyte Biotech Inc. (OTCMKTS:PMCB) back on the radar, for the same reason.
After more than a year's worth of miserable performance from the stock, Cardica, Inc. (NASDAQ:CRDC) shares are soaring, up 36% today on the heels of news that its surgical stapling device has been cleared by the FDA for far more uses than had been previously permitted. The news doesn't come as a complete shock to CRDC owners, though that's certainty didn't start to materialize until after January 7th when the company announced a new partnership agreement with Intuitive Surgical that vaguely suggested good news was on the way. And, even the inkling of good news didn't do as much for Cardica shares as the confirmed news did this morning.
In a bigger sense, while pharmaceuticals and specialty drugs were under fire during the latter half of 2015, that weakness also unfairly pressured makers of biotech devices lower. The rebound from CRDC helps to imply the group is in rebound mode now, so for investors looking to pick up other compelling but speculative biotech device ideas may want to add Pharmacyte Biotech Inc. (OTCMKTS:PMCB) if not their portfolio.
Pharmacyte Biotech is the developer of a biotechnology called Cell-In-a-Box, which is making the healthcare industry rethink what's possible in terms of drug delivery.
Pharmacyte Biotech has, in simplest terms, perfected the elusive art of live cell encapsulation. In other words, PMCB is successfully doing what most researchers and biotech companies have struggled to do well (and been unable to do for the long haul) by encapsulating live cells in a package that (1) is small enough to be implanted into a human body, (2) durable enough to resist a body's immune response, and (3) porous enough to allow the healthy cells living inside the encapsulation to operate normally when that patient's own cells aren't doing their job. Cell-in-a-Box is that biotechnology.
It's as much of a process as it is a molecular structure. The first step in their creation is a mix of live cells (that ultimately spur or even become the therapy) and a proprietary polymer that is then dropped into another proprietary polymer. The two polymers react to form a solid object about the size of the head of the pin, with the still-living cells beneath the shell of the tiny sphere. Though only a few millimeters across, the number of living cells inside the tiny bead-sized capsule can be in the thousands.
While it's not a new idea, Pharmacyte has upped the ante, so to speak, on encapsulation. These capsules allow the cells inside to receive nutrients from a body as well as emit certain chemicals, yet they don't let antibodies in and potentially kill the outside, unrecognized cells the way an immune system normally would. And, unlike most other encapsulation efforts, the capsule itself isn't known to degrade.
The implications for such a technology are almost limitless, although Pharmacyte is first focusing on two arenas... pancreatic cancer, and type 1 diabetes.
On the diabetes front, the cells "in the box" would be insulin-producing engineered Magellan cells inside the pinhead-sized beads, which are then surgically deposited in the leg, near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
As for pancreatic cancer, Cell-in-a-Box is a means of placing thousands of live cells that produce a P450 enzyme inside the capsule, which can activate an otherwise inactive form of cancer drug ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
It blurs the line between biotechnology device and biopharmaceuticals... as most next-generation treatments should.
Though there's still more work to be done, as most veteran traders can attest, the market rewards biotech companies reaching milestones by pushing the stock upward. The PMCB premise alone already has plenty of people interested, and with 2016 being a year with lots of catalysts in the queue, now's the time to start taking a closer look.
With that in mind, just this morning the company updated its explanation of its biotechnology and added some new information about Cell-In-a-Box. Newcomers as well as those familiar with Pharmacyte Biotech will want to take a look right here.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/6150096.htm
NGEY, I SENT EMAIL TO NGEY FEW DAYS AGO, GOT THIS RESPONSE TODAY....HUGE!!!!!!!
March 3, 2016
Dear Mr. Cone:v
Thank you for your inquiry.
First of all, I would like to welcome you aboard as a new shareholder of NGEY.
Please accept my apology of not getting back sooner, but with our Moringa announcement on Monday, we have had an unusual amount of response from both Moringa users, suppliers and shareholders alike.
We have some very exciting and lucrative events taking place.
You are correct in stating that I cannot be specific on a lot of these topics until they have been made public, but to answer your questions briefly.
1) Will NGEY be manufacturing the MorningUP protein bars as well as
distributing them? If so, how soon can we expect updates on the progress?
We are currently in the process of testing our Moringa protein bars with several companies for manufacturing and distribution.
The Moringa needs to be blended with other products and has to contain the required amount of Moringa to receive the nutritional benefits from the product
The taste of the product is of utmost concern for the distributors.
We have commitments from many distributors, including both large and small companies.
We are also almost complete with having our Moringa “Certified Organic” by http://www.ics-intl.com/index.html.
This is not required, but this will open our distribution to the Premium markets such as Whole Foods and Trader Joes.
The added benefit is that since our fish are fed Organic Certified Feed, we will be able to sell our Tilapia as Non-GMO Certified to those same Premium markets where Non-GMO Tilapia is selling for $14 a pound!
2) It was mentioned in the letter to shareholders that a partnership is being explored with a Cargill subsidiary. Is this a possibility and if so how soon will we hear about it?
We have had the people from EWOS at our farm to monitor our feed process long before Cargill bought them.
See http://www.bloomberg.com/news/articles/2015-08-17/cargill-to-buy-ewos-for-1-5-billion-to-expand-in-fish-farming.
They are looking for plant protein substitutes for Soybean. They love the idea of Moringa because it has a higher protein content than Soybeans, doesn’t compete with human food, is not subject to the volatility and speculation of the Commodities markets and can grow in the desert so that it doesn’t compete with existing farmland.
I hope this answers your questions in a general way. Please follow our filings and press releases for more detailed information. We also send out a monthly newsletter as well, so please include a mailing address and an email on our contact page and we will add you to the shareholder list.
Sincerely,
Charlotte Luer
Director of Investor Relations
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
RSII 0012 volume looking for it to breakout look $$$$$
ISGP getting started .0009/.001 ..
http://www.otcmarkets.com/stock/ISGP/profile
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$PMCB Cell Encapsulation for Drug Delivery & Disease Treatment
http://www.pharmacytebiotech.com/wp-content/uploads/2015/01/Cellular-Microencapsulation.pdf
Go $PMCB
$ACTL .0002 750 Mil A/S and 415 Mil O/S.
Could be a mover in the coming weeks and even as early as this week..imo
$PMCB January 25th 2016: Austrianova expands its business area
Austrianova announced today that, having completed the set up of its new GMP facility, it is now offering clients a GMP cell banking (Master Cell Bank and Working Cell Bank) as well as a “Fill and Finish” service for cell therapy products, in addition to its encapsulation services and technology. Austrianova is able to offer the production of Master Cell and Working Cell Banks (MCB and WCB) at the size scale required for early (phase 1 and 2) stage clinical trials at highly competitive prices using its state of the art isolator based production facility, assuring that the highest quality standards are adhered to. The company can also fill bulk cell product into syringes or vials in its GMP facility. This new cell banking and filling service is called GMP4Cells. MCB’s and WCB’s are required for all cell therapy products such as stem cell therapies as well as biologics produced from cells such as vaccines, antibodies, recombinant proteins etc. Similarly, many companies, including those developing stem cell lines and products, are seeking high quality economic fill and finish for relative small lots.
“We see this as a natural add-on to our already established Cell-in-a-Box® cell encapsulation technology for which we have recently set up a GMP manufacturing facility in Thailand. This kind of MCB and WCB production as well as “Fill and Finish” services for cells are, however, stand alone services. Although these services are generally available to all customers, they should allow start up companies and academic based cell products, vaccines etc to enter clinical trials in a quality assured manner but at lower cost that other, more conventional, cell banking companies offer” stated Walter H. Gunzburg, Chairman and CTO of Austrianova.
“In addition to our state of the art facility, Austrianova offers services that comply with major international regulatory agencies using a customized German/Swiss based quality assurance system. Our team has many years experience with regulatory agencies around the world and has taken cell therapies into clinical trials” said Brian Salmons, CEO.
http://austrianova.com/news/ewExternalFiles/PR%20GMP4Cells%20.pdf
PKGM DD..
Filing in Florida points to huge things.....
VIXIMO gets 1,000 shares series A shares, non convertible to common but voting preference.
They also get series B shares that are only convertible IF PKGM uplists to NASDAQ, AMEX, or NYSE.
series A shares have a value of $100.00 per share
series B valued at $10.00 per share
Page 5 of the filing shows the requirement for series B to convert to common. Huge wording. Looking at Uplisting sometime in future, possibly before EOY IMO.
http://search.sunbiz.org/Inquiry/CorporationSearch/ConvertTiffToPDF?storagePath=COR\2016\0129\00018961.Tif&documentNumber=P13000081833
Followers
|
86
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
957
|
Created
|
11/03/15
|
Type
|
Premium
|
Moderator MASTER P | |||
Assistants Rambo Rell nyzaria SubPennyPosts Stockteacher80 |
Posts Today
|
0
|
Posts (Total)
|
957
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |